Effect of pegylated phosphatidylserine-containing liposomes in experimental chronic arthritis

Table 2 Statistical analysis of the clinical score of experimental groups

Coefficients	Value	Standard error	t-value	p-valor
A. (Intercepta) control	16.175545	1.07	15.10	-
A. 5 mg/kg	3.60	1.43	2.51	0.0123*
A.10 mg/kg	−1.74	1.89	−0.92	0.35
A.15 mg/kg^a	0.17	1.37	0.12	0.90
MED. (Intercepta) control	10.37	0.60	17.26	-
MED. 5 mg/kg	−0.21	0.90	−0.23	0.81
MED. 10 mg/kg	0.58	1.21	0.47	0.63
MED. 15 mg/kg^a	−3.20	0.84	−3.80	0.0002***
S. (Intercepta) control	2.79	0.42	6.65	-
S. 5 mg/kg	−0.18	0.64	−0.27	0.78
S. 10 mg/kg	0.64	0.76	0.84	0.39
S.15 mg/kg^a	0.40	0.64	0.62	0.53

The data A (asymptote), MED (half-life) and S (scale) are correlated to their respective controls as designated in the table Intercepta. One individual in the PEG-PSL 15 mg/kg group died (a) one day after the booster. P-value < 0.05 (*) and < 0.0001 (***)

ISSN: 2050-6511